index - Myopathies inflammatoires & thérapies innovantes ciblées Accéder directement au contenu

Dernières publications

Chiffres clés

123 Publications avec texte intégral

Open Access

53 %

Mots clés

Adverse drug reactions Idiopathic inflammatory myopathies Antibodies Anticorps anti-agalsidase Multidisciplinarity Sphingosine-1-phosphate COVID-19 Lysosomal storage diseases Active Auto-immunité Immune checkpoint inhibitors Deep immune profiling Myositis Anti‐mitochondrial antibodies Anti-MDA5 autoantibodies Anti-drug antibodies Myocarditis Middle Aged Agalsidase Interferon Antisynthetase syndrome Cancer Auto-antibodies Biomarker Anti-synthetase syndrome Anti-agalsidase antibodies Inborn errors of metabolism Aldosterone Autoimmune diseases Inflammatory myopathy B-lymphocyte Interstitial lung disease Antisynthetase Aged Cytokines Bioelectrical impedance analysis Adeno-associated vector Autoimmunity Biomarkers Muscle AAV antibody Acid-alpha-glucosidase Anémie hémolytique Animals Gene therapy Polymyositis Immunotherapy Assisted communication devices Mass cytometry Adeno-associated virus vector Anti-Mi2 Adjudication AAV vector Pharmacology Prognosis Arthritis AAV humoral immunity Anticorps spécifique des myosites Fabry disease Autoantibodies Anti-IgE IgG AAV Adolescence Male Aldostérone Acute Kidney Injury/epidemiology/etiology IBM Adeno-associated virus Auto‐antibodies Systems biology Amyotrophic lateral sclerosis Machine learning AAV vectors Inflammation IMNM Anti-interleukin-6 Case reports Antibody responses Inclusion body myositis Abnormal movement Myopathy Female Amyotrophy Cardio-oncology Humans Dependovirus/genetics/immunology Skeletal muscle Antisynthétase Analyses multidimensionnelles DM Outcome measures Biopsy B cell homeostasis Autoantibody Myositis and muscle disease Data integration Antiphospholipid syndrome Dermatomyositis Adult Biomarqueurs